Advanced search
Publication Cover
Cancer Investigation Volume 30, 2012 - Issue 10
Submit an article Journal homepage
303
Views
33
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Caio M. Rocha LimaDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,Correspondence[email protected]
,
Soley BayraktarDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,
,
Aurea M. FloresDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,
,
Jessica MacIntyreDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,
,
Alberto MonteroDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,
,
Joaquina C. BarandaDepartment of Medical Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA,
,
John WallmarkAssociates in Oncology/Hematology, PC, Rockville, Maryland, USA,
,
Chia PorteraGenentech, Inc., South San Francisco, California, USA
,
Rajiv RajaGenentech, Inc., South San Francisco, California, USA
,
Howard SternGenentech, Inc., South San Francisco, California, USA
,
Stephanie Royer-JooGenentech, Inc., South San Francisco, California, USA
&
Lukas C. AmlerGenentech, Inc., South San Francisco, California, USA
 show all
Pages 727-731 | Published online: 12 Oct 2012

REFERENCES

  • Cancer Facts and Figures. 2012. Available at: http://www.cancer. org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf
  • O'Neil BH, Goldberg RM. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 2008;13:1074–1083.
  • Loupakis F, Masi G, Vasile E, Falcone A. First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first? Curr Opin Oncol 2008;20:459–465.
  • Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013–2019.
  • Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L, Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070–1077.
  • Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008;15:751–761.
  • Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001–1012.
  • Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010;16:1256–1263.
  • Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031–1039.
  • Stern HM, Padilla M, Wagner K, Amler L, Ashkenazi A. Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. Clin Cancer Res 2010;16:1587–1596.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.